Maria J. Mansilla

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study.

Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study.

Journal: Actas dermo-sifiliograficas

Published: December 30, 2024

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.

Journal: Journal of hematology & oncology

Published: November 05, 2024

Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis.

Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis.

Journal: The Journal of clinical investigation

Published: December 28, 2023

Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration.

Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration.

Journal: Immunotherapy advances

Published: February 16, 2023

Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.

Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.

Journal: Journal of personalized medicine

Published: November 02, 2021

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis.

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis.

Journal: Biomedicines

Published: September 22, 2021

Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator.

Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator.

Journal: International journal of molecular sciences

Published: May 26, 2021

Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional Hyporesponsiveness.

Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional Hyporesponsiveness.

Journal: Frontiers in immunology

Published: August 27, 2020

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.

Journal: Cellular & molecular immunology

Published: July 13, 2020

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Journal: BMJ open

Published: September 11, 2019

MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients.

MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients.

Journal: Frontiers in immunology

Published: December 18, 2018

Comparison of dendritic cells obtained from autoimmunty-prone and resistant rats.

Comparison of dendritic cells obtained from autoimmunty-prone and resistant rats.

Journal: Immunobiology

Published: December 03, 2018

Showing 1-12 of 38

Last Updated: 09/26/2026